97 related articles for article (PubMed ID: 29502405)
1. 4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships.
Roberts RS; Sevilla S; Ferrer M; Taltavull J; Hernández B; Segarra V; Gràcia J; Lehner MD; Gavaldà A; Andrés M; Cabedo J; Vilella D; Eichhorn P; Calama E; Carcasona C; Miralpeix M
J Med Chem; 2018 Mar; 61(6):2472-2489. PubMed ID: 29502405
[TBL] [Abstract][Full Text] [Related]
2. Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.
Gràcia J; Buil MA; Castro J; Eichhorn P; Ferrer M; Gavaldà A; Hernández B; Segarra V; Lehner MD; Moreno I; Pagès L; Roberts RS; Serrat J; Sevilla S; Taltavull J; Andrés M; Cabedo J; Vilella D; Calama E; Carcasona C; Miralpeix M
J Med Chem; 2016 Dec; 59(23):10479-10497. PubMed ID: 27933955
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors.
Guariento S; Karawajczyk A; Bull JA; Marchini G; Bielska M; Iwanowa X; Bruno O; Fossa P; Giordanetto F
Bioorg Med Chem Lett; 2017 Jan; 27(1):24-29. PubMed ID: 27890378
[TBL] [Abstract][Full Text] [Related]
4. Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.
De Savi C; Cox RJ; Warner DJ; Cook AR; Dickinson MR; McDonough A; Morrill LC; Parker B; Andrews G; Young SS; Gilmour PS; Riley R; Dearman MS
J Med Chem; 2014 Jun; 57(11):4661-76. PubMed ID: 24785301
[TBL] [Abstract][Full Text] [Related]
5. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
[TBL] [Abstract][Full Text] [Related]
6. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
[TBL] [Abstract][Full Text] [Related]
7. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Carzaniga L; Amari G; Rizzi A; Capaldi C; De Fanti R; Ghidini E; Villetti G; Carnini C; Moretto N; Facchinetti F; Caruso P; Marchini G; Battipaglia L; Patacchini R; Cenacchi V; Volta R; Amadei F; Pappani A; Capacchi S; Bagnacani V; Delcanale M; Puccini P; Catinella S; Civelli M; Armani E
J Med Chem; 2017 Dec; 60(24):10026-10046. PubMed ID: 29200281
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
Chapman RW; House A; Richard J; Prelusky D; Lamca J; Wang P; Lundell D; Wu P; Ting PC; Lee JF; Aslanian R; Phillips JE
Eur J Pharmacol; 2010 Sep; 643(2-3):274-81. PubMed ID: 20621091
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).
Press NJ; Taylor RJ; Fullerton JD; Tranter P; McCarthy C; Keller TH; Arnold N; Beer D; Brown L; Cheung R; Christie J; Denholm A; Haberthuer S; Hatto JD; Keenan M; Mercer MK; Oakman H; Sahri H; Tuffnell AR; Tweed M; Trifilieff A
J Med Chem; 2015 Sep; 58(17):6747-52. PubMed ID: 26288344
[TBL] [Abstract][Full Text] [Related]
12. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.
Guay D; Boulet L; Friesen RW; Girard M; Hamel P; Huang Z; Laliberté F; Laliberté S; Mancini JA; Muise E; Pon D; Styhler A
Bioorg Med Chem Lett; 2008 Oct; 18(20):5554-8. PubMed ID: 18835163
[TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects.
Zhou F; Huang Y; Liu L; Song Z; Hou KQ; Yang Y; Luo HB; Huang YY; Xiong XF
Biochem Pharmacol; 2022 Aug; 202():115123. PubMed ID: 35688178
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.
Poondra RR; Nallamelli RV; Meda CL; Srinivas BN; Grover A; Muttabathula J; Voleti SR; Sridhar B; Pal M; Parsa KV
Bioorg Med Chem Lett; 2013 Feb; 23(4):1104-9. PubMed ID: 23294698
[TBL] [Abstract][Full Text] [Related]
15. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
16. Discovery of oral and inhaled PDE4 inhibitors.
Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
[TBL] [Abstract][Full Text] [Related]
17. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
[TBL] [Abstract][Full Text] [Related]
18. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
Nials AT; Tralau-Stewart CJ; Gascoigne MH; Ball DI; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):137-44. PubMed ID: 21205924
[TBL] [Abstract][Full Text] [Related]
19. Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
Armani E; Amari G; Rizzi A; De Fanti R; Ghidini E; Capaldi C; Carzaniga L; Caruso P; Guala M; Peretto I; La Porta E; Bolzoni PT; Facchinetti F; Carnini C; Moretto N; Patacchini R; Bassani F; Cenacchi V; Volta R; Amadei F; Capacchi S; Delcanale M; Puccini P; Catinella S; Civelli M; Villetti G
J Med Chem; 2014 Feb; 57(3):793-816. PubMed ID: 24400806
[TBL] [Abstract][Full Text] [Related]
20. Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
Kawasaki M; Fusano A; Nigo T; Nakamura S; Ito MN; Teranishi Y; Matsumoto S; Toda H; Nomura N; Sumiyoshi T
Bioorg Med Chem Lett; 2014 Jun; 24(12):2689-92. PubMed ID: 24794103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
